PPWP
MRNA icon

Premier Path Wealth Partners’s Moderna MRNA Stock Holding History

Premier Path Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+3,231
New +$167K 0.03% 385
2024
Q3 		– Sell
-2,380
Closed -$283K – 378
2024
Q2 		$283K Buy
+2,380
New +$301K 0.05% 304

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Premier Path Wealth Partners's MRNA Position: Q2 2026 in Review

Premier Path Wealth Partners opened a new position in Moderna (MRNA) in Q2 2026: 3,231 shares worth $226K. The stake represents 0.03% of the portfolio and ranks #385 among its holdings. This is a return to the name: Premier Path Wealth Partners previously reported a position in MRNA as recently as Q2 2024.

Premier Path Wealth Partners first reported a position in MRNA in Q2 2024 and has held it in 2 quarters since. The position peaked at $283K in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Premier Path Wealth Partners held 3,231 shares of Moderna worth $226K as of Q2 2026.
  • Moderna was a new Premier Path Wealth Partners position in Q2 2026.
  • Moderna made up 0.03% of Premier Path Wealth Partners's portfolio in Q2 2026, its #385 holding.
  • Premier Path Wealth Partners first reported a position in Moderna in Q2 2024 and has held it in 2 quarters since.
  • Premier Path Wealth Partners's Moderna position peaked at $283K in Q2 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.